C83.33

Diffuse large B-cell lymphoma, intra-abdominal lymph nodes

Diffuse Large B-cell Lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma, characterized by its aggressive growth and diffuse proliferation of large neoplastic B cells with a high proliferative index. When DLBCL affects the intra-abdominal lymph nodes, it specifically involves lymph nodes located within the abdominal cavity, such as mesenteric, retroperitoneal, or para-aortic nodes. This particular localization can lead to distinct clinical presentations and diagnostic challenges due to the proximity to vital organs and extensive vascular and lymphatic networks. Patients often present with non-specific abdominal symptoms, including pain, discomfort, distension, or a palpable abdominal mass resulting from significantly enlarged lymph nodes. Systemic 'B symptoms' – unexplained fever, drenching night sweats, and significant unintentional weight loss – are frequently present and can be the initial presenting complaints, prompting clinical investigation. Involvement of intra-abdominal nodes may also cause symptoms related to compression of adjacent structures, such as bowel obstruction, hydronephrosis (if retroperitoneal nodes compress the ureters), or ascites due to lymphatic obstruction or peritoneal involvement. Diagnosis is typically initiated with imaging modalities like computed tomography (CT) or positron emission tomography-computed tomography (PET-CT) to identify the extent of involved lymph nodes and assess metabolic activity. Definitive diagnosis requires a biopsy (often image-guided) of the affected lymph node for comprehensive histopathological confirmation and immunophenotyping. This is crucial for distinguishing DLBCL from other types of lymphoma or benign conditions and for identifying specific molecular subtypes (e.g., germinal center B-cell-like vs. activated B-cell-like) which significantly influence prognosis and therapeutic strategies. Staging, involving bone marrow biopsy, cerebrospinal fluid (CSF) analysis (especially for patients with risk factors for central nervous system involvement), and further detailed imaging, is paramount for guiding treatment decisions. The standard treatment typically involves a multi-agent chemotherapy regimen, most commonly R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone), with potential adjustments based on the International Prognostic Index (IPI) score, disease stage, patient comorbidities, and molecular characteristics. Radiation therapy may be considered for bulky disease or localized involvement. Prognosis for DLBCL in intra-abdominal lymph nodes varies based on these factors, emphasizing the need for accurate diagnosis and tailored management.

Clinical Symptoms

  • Abdominal pain or discomfort
  • Abdominal distension
  • Palpable abdominal mass
  • Early satiety
  • Nausea and vomiting (due to bowel compression)
  • Changes in bowel habits (constipation or diarrhea)
  • Unexplained weight loss (B symptom)
  • Fever (B symptom)
  • Drenching night sweats (B symptom)
  • Ascites
  • Jaundice (if biliary obstruction)
  • Hydronephrosis (if ureteral compression)

Common Causes

  • Immunodeficiency (e.g., HIV/AIDS, post-transplant immunosuppression, congenital immunodeficiency syndromes)
  • Autoimmune diseases (e.g., Sjögren's syndrome, rheumatoid arthritis, systemic lupus erythematosus)
  • Prior infections (e.g., Epstein-Barr virus (EBV), Helicobacter pylori)
  • Exposure to certain chemicals (e.g., pesticides, herbicides)
  • Advanced age
  • Genetic predisposition (less common but possible)
  • Prior chemotherapy or radiation therapy for other cancers

Documentation & Coding Tips

Clearly document the definitive diagnosis of Diffuse Large B-cell Lymphoma (DLBCL) and the specific intra-abdominal lymph node involvement, ensuring it is explicitly linked to pathology reports.

Example: DIAGNOSIS: Diffuse Large B-cell Lymphoma (DLBCL), intra-abdominal lymph nodes (C83.33). This diagnosis is confirmed by biopsy of a mesenteric lymph node on 2023-10-26 (Pathology Report #P23-12345). Patient presents for Cycle 2 of R-CHOP therapy. Assessment notes stable disease based on recent PET/CT. Current active disease requiring ongoing systemic therapy. Patient has baseline anemia of chronic disease due to malignancy (D63.0) managed with erythropoietin.

Billing Focus: Specifying 'intra-abdominal lymph nodes' links directly to C83.33, ensuring the highest level of anatomical specificity. Explicitly stating 'active disease requiring ongoing systemic therapy' supports medical necessity for chemotherapy.

Detail the current stage of the lymphoma (e.g., Ann Arbor staging) and whether the disease is active, in remission, or relapsed, along with the treatment plan and patient's response.

Example: DIAGNOSIS: Diffuse Large B-cell Lymphoma, intra-abdominal lymph nodes (C83.33), Stage IIE (Ann Arbor staging). Disease is active, currently undergoing initial definitive chemotherapy. Patient completed Cycle 4 of R-CHOP and shows partial response based on interval PET/CT findings (reduction in SUV max from 15 to 8 in the largest retroperitoneal lymph node, 2024-01-15). Patient continues to experience Grade 2 chemotherapy-induced neutropenia (D70.1) requiring Filgrastim support, and Grade 1 peripheral neuropathy (G62.9) from vincristine.

Billing Focus: The specific staging (IIE) and status ('active,' 'partial response') provide critical information for treatment planning and justification of intensive therapies. Documentation of specific adverse effects (e.g., 'chemotherapy-induced neutropenia,' 'peripheral neuropathy') directly supports billing for management of these complications.

Document all relevant symptoms, manifestations, and complications clearly linked to the lymphoma or its treatment, including 'B symptoms' if present.

Example: HPI: 68 y/o male with known C83.33 DLBCL of mesenteric and retroperitoneal lymph nodes presents with complaints of persistent night sweats (present >1 month, requiring linen changes daily), unintentional weight loss of 10 lbs over 2 months despite adequate caloric intake, and intermittent fevers (max 101.5F, typically resolves spontaneously). These 'B symptoms' are attributed to the active lymphoma. Also reports mild abdominal discomfort, stable from prior visit. No new obstructive symptoms. Patient requires ongoing pain management for abdominal discomfort with acetaminophen.

Billing Focus: Explicitly documenting 'B symptoms' (night sweats, weight loss, fevers) and attributing them to the 'active lymphoma' provides strong medical necessity for diagnostic workup, monitoring, and treatment intensification. Documenting 'abdominal discomfort' as stable from prior visit indicates ongoing monitoring.

Relevant CPT Codes

Related Diagnoses

Hierarchy